Pharma News, 2024

Multiple factors contribute to someone’s risk of developing cancer. Obesity is one risk factor that can increase the risk of some cancer types. Researchers are interested in discovering strategies t...

The subcutaneous formulation of Roche’s blockbuster Ocrevus will cut hospital treatment time for patients. England’s National Health Service (NHS) has said that multiple sclerosis patients...

Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candidates with one showing the most favorable profile

AB-1005 is a gene therapy developed based on adeno-associated viral vector serotype 2 containing the human glial cell line-derived neurotrophic factor (AAV2-GDNF) transgene, evaluated as a pot...

AB-1005 is an investigational adeno-associated virus 2 glial cell line-derived neurotrophic factor (AAV2-GDNF) neurorestorative gene therapy.

The deal strengthens Merz’s market position in Parkinson’s disease while expanding into the multiple sclerosis sector.

Leqembi is intended for patients with mild cognitive impairment or at the mild dementia stage of the disease. Leqembi is the first treatment proven to slow the progression of AD.

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

Trials assessed the drug’s safety and efficacy, with one Phase I/IIa trial conducted in the country and an external Phase I trial. AusperBio Therapeutics and Ausper Biopharma have gained breakthroug...

A. baumannii is most commonly responsible for urinary tract infections, ventilator-associated pneumonia, central line-associated bloodstream infections, persistent wound infections and meningitis

Ivermectin is an attractive cancer drug candidate as it’s inexpensive and already clinically approved, albeit for parasitic infections. Some preclinical studies have indeed found promising result...

IGC Pharma, Inc. today announced preclinical data demonstrating TGR-63’s potential as an effective treatment for Alzheimer’s disease. Analysis of the partition coefficient and mass spectrometry of...